Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer

F. Andriani, P. Perego, N. Carenini, G. Sozzi, L. Roz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To evaluate the relevance of fragile histidine triad (FHIT) status in relation to drug treatment, we analyzed the sensitivity of the Fhit-negative non-small cell lung cancer (NSCLC) cell line NCI-H460 to different drugs, after treatment with an adenoviral vector expressing the FHIT transgene. Expression of Fhit resulted in reduced sensitivity to etoposide, doxorubicin, and topotecan. This feature was associated with Fhit-induced down-regulation of DNA topoisomerases I and II. In contrast, regulation expression of Fhit did not modulate sensitivity to Taxol, but produced a slight increase in sensitivity to cisplatin, as shown by colony-forming assays. Analysis of apoptosis revealed that, after cisplatin exposure, the number of apoptotic cells was two-fold higher in Fhit-expressing H460 cells. Moreover, it appeared that wild-type p53 was required for sensitization to cisplatin type because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Fhit could also partially restore sensitivity to cisplatin in Bcl-2- and Bcl-xL-overexpressing H460 cells that are normally resistant to this drug. Our results support the possible relevance of FHIT in cisplatin-based chemotherapy as well as in the reversal of drug resistance in NSCLC.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalNeoplasia (United States)
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Histidine
Non-Small Cell Lung Carcinoma
Cisplatin
Cell Line
Genes
Pharmaceutical Preparations
Topotecan
Type II DNA Topoisomerase
Type I DNA Topoisomerase
Etoposide
Paclitaxel
Transgenes
Drug Resistance
Doxorubicin
Down-Regulation
Cell Count
Apoptosis
Drug Therapy
Therapeutics

Keywords

  • Apoptosis
  • Chemosensitivity
  • Cisplatin
  • Fhit
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer. / Andriani, F.; Perego, P.; Carenini, N.; Sozzi, G.; Roz, L.

In: Neoplasia (United States), Vol. 8, No. 1, 01.2006, p. 9-17.

Research output: Contribution to journalArticle

@article{9a86a05381e54625b8df578c3285ab02,
title = "Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer",
abstract = "To evaluate the relevance of fragile histidine triad (FHIT) status in relation to drug treatment, we analyzed the sensitivity of the Fhit-negative non-small cell lung cancer (NSCLC) cell line NCI-H460 to different drugs, after treatment with an adenoviral vector expressing the FHIT transgene. Expression of Fhit resulted in reduced sensitivity to etoposide, doxorubicin, and topotecan. This feature was associated with Fhit-induced down-regulation of DNA topoisomerases I and II. In contrast, regulation expression of Fhit did not modulate sensitivity to Taxol, but produced a slight increase in sensitivity to cisplatin, as shown by colony-forming assays. Analysis of apoptosis revealed that, after cisplatin exposure, the number of apoptotic cells was two-fold higher in Fhit-expressing H460 cells. Moreover, it appeared that wild-type p53 was required for sensitization to cisplatin type because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Fhit could also partially restore sensitivity to cisplatin in Bcl-2- and Bcl-xL-overexpressing H460 cells that are normally resistant to this drug. Our results support the possible relevance of FHIT in cisplatin-based chemotherapy as well as in the reversal of drug resistance in NSCLC.",
keywords = "Apoptosis, Chemosensitivity, Cisplatin, Fhit, Lung cancer",
author = "F. Andriani and P. Perego and N. Carenini and G. Sozzi and L. Roz",
year = "2006",
month = "1",
doi = "10.1593/neo.05517",
language = "English",
volume = "8",
pages = "9--17",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer

AU - Andriani, F.

AU - Perego, P.

AU - Carenini, N.

AU - Sozzi, G.

AU - Roz, L.

PY - 2006/1

Y1 - 2006/1

N2 - To evaluate the relevance of fragile histidine triad (FHIT) status in relation to drug treatment, we analyzed the sensitivity of the Fhit-negative non-small cell lung cancer (NSCLC) cell line NCI-H460 to different drugs, after treatment with an adenoviral vector expressing the FHIT transgene. Expression of Fhit resulted in reduced sensitivity to etoposide, doxorubicin, and topotecan. This feature was associated with Fhit-induced down-regulation of DNA topoisomerases I and II. In contrast, regulation expression of Fhit did not modulate sensitivity to Taxol, but produced a slight increase in sensitivity to cisplatin, as shown by colony-forming assays. Analysis of apoptosis revealed that, after cisplatin exposure, the number of apoptotic cells was two-fold higher in Fhit-expressing H460 cells. Moreover, it appeared that wild-type p53 was required for sensitization to cisplatin type because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Fhit could also partially restore sensitivity to cisplatin in Bcl-2- and Bcl-xL-overexpressing H460 cells that are normally resistant to this drug. Our results support the possible relevance of FHIT in cisplatin-based chemotherapy as well as in the reversal of drug resistance in NSCLC.

AB - To evaluate the relevance of fragile histidine triad (FHIT) status in relation to drug treatment, we analyzed the sensitivity of the Fhit-negative non-small cell lung cancer (NSCLC) cell line NCI-H460 to different drugs, after treatment with an adenoviral vector expressing the FHIT transgene. Expression of Fhit resulted in reduced sensitivity to etoposide, doxorubicin, and topotecan. This feature was associated with Fhit-induced down-regulation of DNA topoisomerases I and II. In contrast, regulation expression of Fhit did not modulate sensitivity to Taxol, but produced a slight increase in sensitivity to cisplatin, as shown by colony-forming assays. Analysis of apoptosis revealed that, after cisplatin exposure, the number of apoptotic cells was two-fold higher in Fhit-expressing H460 cells. Moreover, it appeared that wild-type p53 was required for sensitization to cisplatin type because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Fhit could also partially restore sensitivity to cisplatin in Bcl-2- and Bcl-xL-overexpressing H460 cells that are normally resistant to this drug. Our results support the possible relevance of FHIT in cisplatin-based chemotherapy as well as in the reversal of drug resistance in NSCLC.

KW - Apoptosis

KW - Chemosensitivity

KW - Cisplatin

KW - Fhit

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=33646435805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646435805&partnerID=8YFLogxK

U2 - 10.1593/neo.05517

DO - 10.1593/neo.05517

M3 - Article

C2 - 16533421

AN - SCOPUS:33646435805

VL - 8

SP - 9

EP - 17

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 1

ER -